Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Health and Life Sciences at the Edge: Privacy Frameworks in Health and Life Sciences

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want MarketScale to feature Healthcare?

Book a 15-minute demo and we'll map your Healthcare expertise to the content buyers are searching for.

Book a demo

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare and life science applications? This is the question host Hilary Kennedy posed to BeeKeeperAI’s CEO Michael Blum, MD and Intel’s Health and Life Sciences General Manager, Chris Gough.

“Even large health organizations do not have the diversity, quality, or amount of data required to create high-quality, generalizable AI,” said Blum. “The solution is a federated framework that allows each data steward to ensure the privacy of their data by keeping it in their protected cloud, while validating and training AI across all of those stewards.”

Gough agreed, saying, “If you can reduce the friction to accessing large, diverse, high-quality data sets – and use those data sets as part of the AI training step – then the algorithms that result will be more accurate for multiple populations.”

“Healthcare AI is projected to be a $46 billion dollar market. When you turn that into human impact, there’s a tremendous opportunity to improve the quality of care and reduce the cost of care,” said Blum. “But the challenge we see over-and-over again is that the algorithms don’t generalize across populations. Their accuracy and performance fall off dramatically. We have to get rapid access to much broader and much more diverse data sets.”

“We really have a supply and demand problem in healthcare,” Gough added. “AI will help the industry better target the scarce resources it has, allowing organizations to be less reactive and more proactive and predictive.”

To learn more about Michael Blum, MD, and Chris Gough:

Connect with them on LinkedIn

Visit https://www.beekeeperai.com/

Read the “Privacy-Preserving Data-Collaboration Methods that Accelerate Healthcare Innovation” white paper: https://www.intel.com/content/www/us/en/healthcare-it/resources/confidential-computing-whitepaper.html

Subscribe to this channel on Apple Podcasts, Spotify, or Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The Cost of Waiting: Why Healthcare Can't Afford Slow Decisions with Mark Van Sumeren

The healthcare industry faces significant consequences when delayed decision-making occurs. Prompt and efficient action is crucial to prevent adverse impacts on patient care and operational efficiency. Addressing this issue requires a commitment to more agile and informed decision processes.

  • 01Delayed decision-making in healthcare can lead to negative impacts on patient care and operational efficiency.
  • 02Healthcare organizations are encouraged to adopt agile decision-making processes to improve effectiveness.
  • 03Implementing informed and prompt decision-making strategies can mitigate the risks of inefficiencies and poor patient outcomes.

Aug 17, 2026

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

Medicare's ACCESS pilot is live, but patients can't find which providers offer it

The Centers for Medicare & Medicaid Services (CMS) launched its tech-enabled chronic care pilot program, known as the ACCESS pilot. Despite its initiation, a significant issue persists as patients struggle to find which healthcare providers are participating in the program. Meanwhile, the FDA has authorized 115 AI-based medical devices in 2021.

  • 01CMS has initiated the ACCESS pilot program to enhance chronic care management using technology.
  • 02Patients are facing challenges in identifying healthcare providers involved in the ACCESS pilot.
  • 03In 2021, the FDA authorized 115 AI-based medical devices.

Aug 17, 2026

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

Sobi CEO Guido Oelkers named BioNTech's next chief executive, targeting multiple approved products by 2030

BioNTech has appointed Guido Oelkers, the current CEO of Sobi, as its next chief executive. Oelkers is tasked with advancing BioNTech's oncology pipeline to achieve multiple approved products by 2030.

  • 01BioNTech has selected Guido Oelkers as its new CEO, effective soon.
  • 02Guido Oelkers aims to turn BioNTech's deep oncology pipeline into several approved products by 2030.

Aug 17, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512